INTRODUCTION {#h0.0}
============

The rising prevalence of obesity and its comorbidities, including type 2 diabetes, hypertension, and cardiovascular disease, requires further efforts to better understand the pathogenesis of these conditions. In humans and mice, obesity is accompanied by a reduction of intestinal *Bacteroidetes* and a concomitant increase of *Firmicutes* ([@B1], [@B2]). However, this finding was not confirmed in other human studies, which did not show an increased *Firmicutes*/*Bacteroidetes* ratio in obese subjects ([@B3], [@B4]). The high proportion of *Firmicutes* observed in obese mice was in part due to the proliferation of *Erysipelotrichi*, a bacterial class within this phylum ([@B5]). An increased abundance of intestinal *Erysipelotrichi* was also observed in mice fed a Western diet ([@B6], [@B7]) and in an obese human individual ([@B8]). This bloom of *Erysipelotrichi* suggests a role of these bacteria in obesity development. A recent study in type 2 diabetic women linked the presence of *Clostridium ramosum*, a member of the *Erysipelotrichi*, to symptoms of the metabolic syndrome ([@B9]). In support of this finding, obesity in human subjects was associated with low bacterial gene content and increased abundance of *C. ramosum* ([@B10]). These studies suggest that *C. ramosum* may be critically involved in obesity development. However, the underlying mechanisms are obscure.

Several mechanisms have been proposed to explain obesogenic effects of intestinal bacteria. Bacterial glycoside hydrolases cleave nondigestible polysaccharides (dietary fiber) to oligo- and monosaccharides, which subsequently undergo bacterial fermentation mainly to short-chain fatty acids (SCFA). The latter provide additional energy to the host ([@B7], [@B11], [@B12]). Glucose released during bacterial depolymerization of polysaccharides may promote hepatic lipogenesis ([@B13]) and could thereby contribute to obesity development. High-fat diets (HFD) increase intestinal permeability and thereby facilitate the absorption of bacterial lipopolysaccharides (LPS) ([@B14], [@B15]). Increased serum LPS levels were identified as one major cause of obesity-associated low-grade inflammation. Other possible links between obesity and intestinal bacteria include the microbial modulation of appetite ([@B16]) or of intestinal lipid absorption ([@B17]).

To test the hypothesis that *C. ramosum* has obesogenic properties, we used gnotobiotic mice harboring a simplified human intestinal microbiota (SIHUMI) composed of eight bacterial species, including *C. ramosum*, and compared them with mice harboring the same microbial community but without *C. ramosum* (SIHUMIw/oCra). We hypothesized that SIHUMI mice fed a high-fat diet (HFD) for 4 weeks develop severe obesity, while SIHUMIw/oCra mice will develop no or only moderate obesity. Mice monoassociated with *C. ramosum* (Cra mice) were investigated to characterize the possible obesogenic effect of this bacterium in the absence of other community members. To elucidate how *C. ramosum* may contribute to obesity, we tested if this bacterial species (i) increases energy extraction from the diet by delivering SCFA, (ii) facilitates glucose or lipid uptake in the intestine, and/or (iii) reduces gut barrier integrity. The comparison of SIHUMI and SIHUMIw/oCra mice allows a direct link of the observed effects with the presence or the absence of this bacterial species in a defined microbial community.

RESULTS {#h1}
=======

High-fat diet feeding induces obesity and increases the proportion of *C. ramosum* in SIHUMI mice. {#h1.1}
--------------------------------------------------------------------------------------------------

After 4 weeks of dietary intervention, SIHUMI mice fed the low-fat diet (LFD) stayed lean, whereas SIHUMI mice fed the HFD became obese. Accordingly, LFD-fed SIHUMI mice gained less body weight than HFD-fed SIHUMI mice (5.35% ± 3.31% versus 19.94% ± 3.98%, *P* = 0.014) and had lower body fat percentages than HFD-fed SIHUMI mice (28.78% ± 0.88% versus 32.61% ± 1.10%, *P* = 0.017). Obesity in HFD-fed SIHUMI mice was accompanied by a higher proportion of *C. ramosum* in cecal (*P* = 0.003) ([Fig. 1](#fig1){ref-type="fig"}) and colonic (LFD, 5% ± 1%, versus HFD, 16% ± 2%, of total bacteria; *P* \< 0.001) contents. (For absolute cell counts of all bacterial species, see [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material.) Cecal and colonic cell counts of *C. ramosum* in HFD-fed SIHUMI mice (9.34 ± 0.07 and 9.31 ± 0.06 log~10~ cells/g dry weight, respectively) were approximately 0.5 log~10~ cells/g dry weight higher (*P* \< 0.001) than those in LFD-fed SIHUMI mice (8.83 ± 0.04 and 8.77 ± 0.05 log~10~ cells/g dry weight, respectively). Total bacterial cell counts in cecum (10.24 ± 0.06 versus 10.14 ± 0.04 log~10~ cells/g dry weight) and colon (10.05 ± 0.02 versus 10.05 ± 0.06 log~10~ cells/g dry weight) did not differ between LFD-fed and HFD-fed SIHUMI mice. Our finding and the reported associations of *C. ramosum* with obesity ([@B9], [@B10], [@B18]) suggest a contribution of this bacterium to obesity development. Therefore, a possible obesogenic effect of *C. ramosum* was investigated in gnotobiotic mice fed HFD.

![High-fat diet feeding for 4 weeks increases the cecal proportion of *Clostridium ramosum* (red) in mice harboring a simplified human intestinal microbiota (SIHUMI) compared with SIHUMI mice fed a low-fat diet for 4 weeks. Bacterial cell numbers were determined by fluorescence *in situ* hybridization or plating on Rogosa agar (*Lactobacillus plantarum*). Mean values ± standard errors of the means (SEM) are shown. *n* = 8 mice per group. For absolute bacterial cell counts, see [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material.](mbo0051420090001){#fig1}

Presence of *C. ramosum* in gnotobiotic mice fed a semisynthetic HFD promotes obesity. {#h1.2}
--------------------------------------------------------------------------------------

To test the hypothesis that *C. ramosum* contributes to diet-induced obesity, we compared SIHUMI, SIHUMIw/oCra, and Cra mice fed HFD. After 4 weeks of HFD feeding, both SIHUMI mice and Cra mice displayed increased body weight gain, body fat percentages ([Fig. 2](#fig2){ref-type="fig"}), and adipose tissue weights compared with SIHUMIw/oCra mice ([Table 1](#tab1){ref-type="table"}). On the LFD, the mouse groups did not differ in body weight gain and body fat percentage (see [Fig. S1](#figS1){ref-type="supplementary-material"} in the supplemental material), indicating that the obesogenic effect of *C. ramosum* was restricted to the HFD intervention. HFD-fed SIHUMI and HFD-fed SIHUMIw/oCra mice did not differ in their blood glucose concentrations during the oral glucose tolerance test. However, the blood glucose level in HFD-fed Cra mice decreased more slowly than those in the other two mouse groups ([Fig. 2C](#fig2){ref-type="fig"}).

![*Clostridium ramosum* increases symptoms of obesity in mice harboring a simplified human intestinal microbiota (SIHUMI) or *C. ramosum* only (Cra) compared with SIHUMI mice without *C. ramosum* (SIHUMIw/oCra) after 4 weeks of high-fat diet feeding. (A) Relative body weight gain. (B) Body fat percentage. (C) Blood glucose concentration during oral glucose tolerance test. Mean values ± SEM are shown. *n* = 8 to 9 mice per group, except for the body fat percentage of Cra mice, for which *n* = 3, and for the blood glucose concentration of SIHUMI mice, for which *n* = 4. \*\*, *P* \< 0.01 for SIHUMI versus SIHUMIw/oCra mice; \#, *P* \< 0.05, and \#\#, *P* \< 0.01, for Cra versus SIHUMIw/oCra mice.](mbo0051420090002){#fig2}

###### 

Biometric parameters of SIHUMI, SIHUMIw/oCra, or Cra mice, all fed an HFD for 4 weeks

  Parameter^[*a*](#ngtab1.1)^                 Result for mice^[*b*](#ngtab1.2)^                          
  ------------------------------------------- ----------------------------------- ---------------------- ----------------------
  Body wt (g)                                                                                            
      Wk 0                                    27.79 ± 0.55                        27.11 ± 0.62 (0.469)   28.18 ± 0.49 (0.613)
      Wk 4                                    29.12 ± 0.41                        32.43 ± 0.86 (0.003)   31.83 ± 0.75 (0.005)
  Wt gain (g \[wk 4\])                         1.33 ± 0.40                         5.31 ± 0.95 (0.001)    3.65 ± 0.70 (0.009)
  eWAT (mg/g body wt)                         18.46 ± 2.47                        28.31 ± 4.23 (0.056)   32.49 ± 3.74 (0.006)
  mWAT (mg/g body wt)                         11.81 ± 0.56                        16.76 ± 1.40 (0.004)   15.66 ± 1.36 (0.015)
  sWAT (mg/g body wt)                          9.69 ± 1.21                        14.15 ± 1.78 (0.048)   12.87 ± 0.84 (0.052)
  Energy intake (kJ/day)                      81.20 ± 2.03                        87.22 ± 6.99 (0.743)   75.25 ± 2.55 (0.085)
  Food efficiency (mg/kJ)^[*c*](#ngtab1.3)^    0.57 ± 0.17                         2.26 ± 0.40 (0.001)    1.77 ± 0.37 (0.008)
  Digestibility of HFD (%)                    92.57 ± 0.43                        92.27 ± 0.56 (0.681)   92.60 ± 0.64 (0.963)
  Digestible energy (kJ/day \[wk 3\])         72.25 ± 6.76                        70.17 ± 3.97 (0.607)   68.63 ± 5.37 (1.000)

eWAT, epididymal white adipose tissue; mWAT, mesenteric white adipose tissue; sWAT, subcutaneous white adipose tissue.

Values are means ± SEM (*n* = 7 to 9). *P* values for obese SIHUMI or Cra mice versus less obese SIHUMIw/oCra mice (reference) are shown in parentheses.

Calculated from body weight gain (mg) per consumed energy (kJ) after 4 weeks of HFD feeding.

Leptin gene (*Lep*) expression was determined in the HFD-fed mice because this adipocyte-derived hormone signals filled energy stores to the brain ([@B19]). *Lep* mRNA levels in epididymal white adipose tissue (eWAT) of obese SIHUMI mice (1.5-fold, *P* = 0.059) and obese Cra mice (1.8-fold, *P* = 0.174) were slightly higher than those of less obese SIHUMIw/oCra mice. The improved food efficiency observed for SIHUMI and Cra mice indicates a more efficient conversion of dietary energy into body mass by these mice ([Table 1](#tab1){ref-type="table"}). Since all mice received the same HFD and were housed under the same conditions, it may be concluded that the more pronounced obese phenotype observed for the SIHUMI and Cra mice was mediated by the presence of *C. ramosum*. The mouse groups did not differ in their energy intakes and the digestibilities of the HFD ([Table 1](#tab1){ref-type="table"}). Therefore, a still unknown bacterial obesogenic mechanism must be responsible for the observed effects. To find indications on how *C. ramosum* enhanced lipid deposition in SIHUMI and Cra mice in response to HFD feeding, various possible mechanisms were examined.

*C. ramosum* affects liver metabolism in gnotobiotic mice. {#h1.3}
----------------------------------------------------------

Liver weight in obese SIHUMI mice was higher than that in less obese SIHUMIw/oCra mice or obese Cra mice ([Fig. 3A](#fig3){ref-type="fig"}). SIHUMI and Cra mice displayed higher liver triglyceride contents and a tendency for higher liver glycogen contents than SIHUMIw/oCra mice ([Fig. 3B and C](#fig3){ref-type="fig"}). To investigate the impact of *C. ramosum* on liver metabolism in SIHUMI mice in more detail, expression levels of genes involved in lipid transport (fatty acid translocase \[*Cd36*\]), lipid synthesis (acetyl coenzyme A \[acetyl-CoA\] carboxylase 1 \[*Acaca*\] and fatty acid synthase \[*Fasn*\]), triglyceride synthesis (glycerol-3-phosphate acyltransferase 1 \[*Gpat1*\], diacylglycerol acyltransferase 2 \[*Dgat2*\]), cholesterol synthesis (HMG-CoA reductase \[*Hmgcr*\]), and lipid catabolism (peroxisome proliferator-activated receptor alpha \[*Ppara*\] and carnitine palmitoyltransferase 1a \[*Cpt1a*\]) were analyzed ([Fig. 4](#fig4){ref-type="fig"}). The presence of *C. ramosum* in SIHUMI mice reduced the mRNA levels of *Cd36*, *Ppara*, and *Cpt1a* significantly and increased those of *Fasn* (3-fold, *P* = 0.074) compared with those in SIHUMIw/oCra mice ([Fig. 4A, C, G](#fig4){ref-type="fig"}, and H). The data imply reduced lipid uptake and lipid catabolism and elevated fatty acid synthesis in the livers of SIHUMI mice. In contrast to SIHUMI mice, the presence of *C. ramosum* in monoassociated mice increased the mRNA levels of *Acaca* and reduced those of *Gpat1*, indicating increased fatty acid synthesis in conjunction with a reduced triglyceride formation in Cra mice compared with SIHUMIw/oCra mice ([Fig. 4B and D](#fig4){ref-type="fig"}). The mRNA levels of *Cd36*, *Gpat1*, *Ppara*, and *Cpt1a* differed between SIHUMI and Cra mice, suggesting that the effects of *C. ramosum* on liver metabolism are modulated by the presence of other bacterial species.

![Liver parameters of mice harboring a simplified human intestinal microbiota (SIHUMI), SIHUMI without *C. ramosum* (SIHUMIw/oCra), or *C. ramosum* only (Cra). All mice were fed a high-fat diet for 4 weeks. (A) Relative liver weight. (B) Liver triacylglycerol content. (C) Liver glycogen content. Mean values ± SEM are shown. *n* = 8 to 9 mice per group, except for SIHUMI liver weight, for which *n* = 5. \*, *P* \< 0.05, and \*\*, *P* \< 0.01, for obese SIHUMI or Cra mice versus less obese SIHUMIw/oCra mice (reference). n.s., not significant.](mbo0051420090003){#fig3}

![Expression of genes encoding proteins involved in hepatic lipid metabolism in mice harboring a simplified human intestinal microbiota (SIHUMI), SIHUMI without *C. ramosum* (SIHUMIw/oCra) or *C. ramosum* only (Cra) after 4 weeks of high-fat diet feeding. (A) Gene coding for fat transport protein fatty acid translocase (*Cd36*). (B and C) Genes coding for fatty acid synthesis proteins acetyl-CoA carboxylase 1 (*Acaca*) and fatty acid synthase (*Fasn*). (D and E) Genes coding for triglyceride synthesis proteins glycerol-3-phosphate acyltransferase 1 (*Gpat1*) and diacylglycerol acyltransferase 2 (*Dgat2*). (F) Gene coding for cholesterol synthesis protein HMG-CoA reductase (*Hmgcr*). (G and H) Genes coding for fatty acid catabolism proteins peroxisome proliferator-activated receptor alpha (*Ppara*) and carnitine palmitoyltransferase 1a (*Cpt1a*). Mean values ± SEM are shown. *n* = 8 to 9 mice per group. \*, *P* \< 0.05, and \*\*, *P* \< 0.01, for obese SIHUMI or Cra mice versus less obese SIHUMIw/oCra mice (reference). n.s., not significant.](mbo0051420090004){#fig4}

*C. ramosum* increases *Glut2* transcription in small intestine. {#h1.4}
----------------------------------------------------------------

The gut microbiota enhances the extraction of energy from the diet and modulates the expression of genes involved in nutrient absorption and has therefore been proposed to promote obesity development ([@B12], [@B20]). To investigate whether enhanced glucose absorption contributed to the more pronounced obesity of SIHUMI and Cra mice, we analyzed gene expression of two transport proteins involved in small intestinal glucose uptake. The mRNA levels of the gene coding for glucose transporter 2 (*Glut2*), which facilitates passive glucose absorption, was significantly increased in jejunal mucosa of obese SIHUMI mice (2-fold, *P* = 0.015) and obese Cra mice (2.6-fold, *P* = 0.001) compared with less obese SIHUMIw/oCra mice. Moreover, ileal expression of *Glut2* was significantly increased in Cra mice (2.3-fold, *P* = 0.024), whereas the increased ileal *Glut2* expression in SIHUMI mice was not statistically significant (1.6-fold, *P* = 0.250). In contrast to *Glut2* expression, mRNA levels of the gene coding for the sodium/glucose cotransporter 1 in jejunal mucosa (*Slc5a1*) were 1.6-fold lower in SIHUMI mice (*P* = 0.007) and Cra mice (*P* = 0.004) than in SIHUMIw/oCra mice. Levels of ileal *Slc5a1* gene expression did not differ between the groups. These data indicate that the obesogenic effect of *C. ramosum* might, at least in part, be mediated by *Glut2*, which elevates glucose absorption.

*C. ramosum* increases intestinal SCFA formation in obese SIHUMI mice but not in obese Cra mice. {#h1.5}
------------------------------------------------------------------------------------------------

In humans, SCFA deliver up to 10% of the daily energy needs ([@B21]). In addition, SCFA are associated with increased *de novo* lipogenesis and body fat storage ([@B22], [@B23]). We therefore investigated whether *C. ramosum* enhanced the formation of SCFA and thereby promoted obesity development in SIHUMI and Cra mice. Acetate concentrations in cecum and colon were higher in SIHUMI mice, but they were lower in Cra mice than in SIHUMIw/oCra mice, all fed HFD ([Table 2](#tab2){ref-type="table"}). To determine the capacity of the microbial communities in SIHUMI and SIHUMIw/oCra mice to form SCFA from HFD, cecal and colonic contents from these mice were incubated under anoxic conditions and SCFA formation was monitored. The *in vitro* SCFA formation rates by intestinal contents did not differ between SIHUMI and SIHUMIw/oCra mice (see [Table S2](#tabS2){ref-type="supplementary-material"} in the supplemental material). In accordance with this result, SCFA concentrations in portal vein plasma of SIHUMI and SIHUMIw/oCra mice were also not different (see [Table S2](#tabS2){ref-type="supplementary-material"}), arguing against SCFA as an important factor for obesity development in this mouse model and against increased SCFA absorption in response to the presence of *C. ramosum*.

###### 

Intestinal concentrations of SCFA in SIHUMI, SIHUMIw/oCra, or Cra mice after 4 weeks of high-fat diet feeding

  SCFA             SCFA concn (µmol/g) in^[*a*](#ngtab2.1)^:                                                              
  ---------------- ------------------------------------------- -------------- ----------------- ------------ ------------ -----------------
  Acetic acid      10.3 ± 0.7                                  15.8 ± 1.9\*   7.6 ± 0.8\*       10.9 ± 0.8   16.2 ± 2.5   7.1 ± 1.2\*
  Propionic acid    1.7 ± 0.2                                   2.8 ± 0.5     0.1 ± 0.0\*\*\*    1.2 ± 0.2    1.5 ± 0.2   0.1 ± 0.0\*\*\*
  Butyric acid      0.4 ± 0.0                                   0.6 ± 0.1     ND                 0.2 ± 0.1    0.2 ± 0.1   ND

Values are means ± SEM (*n* = 8 to 9). ND, not detected. \*, *P* \< 0.05, and \*\*\*, *P* \< 0.001, for obese SIHUMI or Cra mice versus less obese SIHUMIw/oCra mice (reference).

Gene expression of SCFA-related proteins in colonic mucosa was also determined. Expression of the genes coding for monocarboxylate transporter 1 (*Mct1*), which facilitates SCFA transport across the brush border membrane ([@B24], [@B25]), free fatty acid receptor 3 (*Ffar3*), and the downstream-activated gut hormone peptide YY did not differ between SIHUMIw/oCra, SIHUMI, and Cra mice (data not shown). These data suggest that increased formation, uptake, or signaling of SCFA was not causative for obesity development in SIHUMI and Cra mice.

*C. ramosum* increases gene expression of fat transport proteins in ileum. {#h1.6}
--------------------------------------------------------------------------

We hypothesized that *C. ramosum* promoted ileal lipid absorption and thereby contributed to the higher body weight gain and fat deposition in the obese SIHUMI and Cra mice compared with the less obese SIHUMIw/oCra mice. To assess the effect of *C. ramosum* on expression of genes involved in lipid uptake, mRNA levels of the *Cd36* gene and the genes coding for intestinal fatty acid binding protein (*Fabp2*), fatty acid transport protein 4 (*Fatp4*), and lipid storage protein perilipin 2 (*Plin2*) were determined in all groups. Ileal gene expression of *Cd36* was significantly increased in SIHUMI and Cra mice compared with SIHUMIw/oCra mice ([Fig. 5A](#fig5){ref-type="fig"}), while that of *Fabp2* only tended to be higher in SIHUMI (*P* = 0.140) and Cra (*P* = 0.156) mice than in SIHUMIw/oCra mice ([Fig. 5B](#fig5){ref-type="fig"}). Transcription of *Fatp4* and *Plin2* was increased in ileal mucosa of SIHUMI mice but not in that of Cra and SIHUMIw/oCra mice ([Fig. 5C and D](#fig5){ref-type="fig"}). Given that monoassociation of mice with *C. ramosum* did not increase *Fatp4* and *Plin2* expression, we propose that upregulation of these genes by *C. ramosum* was dependent on other members of the SIHUMI community. In conclusion, the data suggest that the obesity-promoting effect of *C. ramosum* is based on the ability of this bacterium, alone or within a microbial community, to enhance expression of genes involved in ileal lipid absorption.

![Expression of genes encoding fat transport and storage proteins in ileal mucosa of mice harboring a simplified human intestinal microbiota (SIHUMI), SIHUMI without *C. ramosum* (SIHUMIw/oCra), or *C. ramosum* only (Cra). Mice were fed a high-fat diet for 4 weeks. (A) Gene coding for fatty acid translocase (*Cd36*). (B) Gene coding for intestinal fatty acid binding protein (*Fabp2*). (C) Gene coding for fatty acid transport protein 4 (*Fatp4*). (D) Gene coding for fat storage protein perilipin 2 (*Plin2*). Mean values ± SEM are shown. *n* = 8 mice per group. \*, *P* \< 0.05, and \*\*, *P* \< 0.01, for obese SIHUMI or Cra mice versus less obese SIHUMIw/oCra mice (reference). n.s., not significant.](mbo0051420090005){#fig5}

*C. ramosum* does not increase gut permeability and does not cause low-grade inflammation. {#h1.7}
------------------------------------------------------------------------------------------

Obesity is often associated with increased levels of inflammatory markers referred to as low-grade inflammation ([@B26]). Diets rich in fat facilitate the uptake of bacterial lipopolysaccharide (LPS), resulting in endotoxemia, an increased inflammatory tone, adiposity, and various symptoms of metabolic disease ([@B27]). This has been linked to an HFD-mediated impairment of gut barrier function ([@B14], [@B15]). To investigate whether *C. ramosum* impairs gut epithelial barrier function, we determined intestinal permeability by measuring the concentration of 4-kDa fluorescein isothiocyanate (FITC)-labeled dextran in plasma following its oral application. High plasma FITC-dextran concentrations indicate increased gut permeability ([@B14]). However, SIHUMIw/oCra, SIHUMI, and Cra mice did not differ in their FITC-dextran plasma levels ([Table 3](#tab3){ref-type="table"}). Levels of expression of the genes coding for the tight junction proteins zonula occludens-1 (*Zo1*) and occludin (*Ocln*) in small intestinal mucosa were similar in SIHUMIw/oCra, SIHUMI, and Cra mice. SIHUMI and Cra mice even displayed an increased colonic transcription of *Zo1* and *Ocln* ([Table 3](#tab3){ref-type="table"}), arguing also against a disturbed gut barrier in mice harboring *C. ramosum*. In line with the expression data of epithelial barrier-associated genes, LPS concentrations in all samples were close to or below the detection limit of the method (0.05 IU/ml) ([Table 3](#tab3){ref-type="table"}). Intestinal mRNA levels of the tumor necrosis factor alpha gene (*Tnfa*) tended to be lower in obese SIHUMI and Cra mice than in less obese SIHUMIw/oCra mice. *Tnfa* transcription was only increased in liver of SIHUMI mice and in eWAT of Cra mice compared with SIHUMIw/oCra mice ([Table 3](#tab3){ref-type="table"}). In general, *Tnfa* mRNA levels in all tissues were very low and argue against endotoxemia as a major contributor to obesity in SIHUMI and Cra mice. Taken together, the data demonstrate that the obesogenic effect of *C. ramosum* in gnotobiotic mice does not involve impaired gut barrier function or endotoxemia.

###### 

Parameters of intestinal permeability and low-grade inflammation in SIHUMI, SIHUMIw/oCra, or Cra mice after 4 weeks of high-fat diet feeding

  Parameter^[*a*](#ngtab3.1)^                        Result for mice^[*b*](#ngtab3.2)^                       
  -------------------------------------------------- ----------------------------------- ------------------- -------------------------------
  Intestinal permeability                                                                                    
      FITC-dextran concn (µg/ml)^[*c*](#ngtab3.3)^   4.55 ± 0.62                         4.00 ± 1.20         3.29 ± 0.28
      *Zo1* relative expression in:                                                                          
          Jejunum                                    1.00 ± 0.37                         1.32 ± 0.42         1.71 ± 0.59^[*d*](#ngtab3.4)^
          Ileum                                      1.00 ± 0.08                         0.87 ± 0.08         1.00 ± 0.08
          Colon                                      1.00 ± 0.12                         1.99 ± 0.09\*\*\*   1.91 ± 0.24\*\*
      *Ocln* relative expression in:                                                                         
          Jejunum                                    1.00 ± 0.08                         0.80 ± 0.12         0.94 ± 0.14
          Ileum                                      1.00 ± 0.06                         0.90 ± 0.07         0.77 ± 0.05\*
          Colon                                      1.00 ± 0.07                         1.56 ± 0.13\*\*     1.10 ± 0.07
  Low-grade inflammation                                                                                     
      LPS concn (IU/ml)^[*c*](#ngtab3.3)^            0.06 ± 0.03                         0.02 ± 0.02         ND
      *Tnfa* relative expression in:                                                                         
          Jejunum                                    1.00 ± 0.14                         0.58 ± 0.17         0.71 ± 0.06
          Ileum                                      1.00 ± 0.14                         0.97 ± 0.12         0.43 ± 0.06\*\*
          Colon                                      1.00 ± 0.13                         0.64 ± 0.09\*       1.21 ± 0.19
          Liver                                      1.00 ± 0.08                         1.99 ± 0.24\*\*     1.24 ± 0.15
          eWAT                                       1.00 ± 0.13                         1.41 ± 0.15         1.78 ± 0.28\*

FITC-dextran, 4 kDa fluorescein isothiocyanate-dextran; LPS, lipopolysaccharides; *Ocln*, occludin gene; *Tnfa*, tumor necrosis factor alpha gene; *Zo1*, zonula occludens-1 gene. Gene expression of *Zo1*, *Ocln*, and *Tnfa* was analyzed in the indicated tissues.

Values are means ± SEM (*n* = 7 to 9). ND, not detected. \*, *P* \< 0.05, \*\*, *P* \< 0.01, and \*\*\*, *P* \< 0.001, for obese SIHUMI or Cra mice versus less obese SIHUMIw/oCra mice (reference).

Determined in peripheral blood plasma.

*n* = 5.

DISCUSSION {#h2}
==========

HFD feeding changes microbial community composition in favor of *C. ramosum*. {#h2.1}
-----------------------------------------------------------------------------

In SIHUMI mice, HFD feeding and the ensuing obesity were accompanied by an increased abundance of intestinal *C. ramosum* ([Fig. 1](#fig1){ref-type="fig"}). An increase of *C. ramosum* in response to HFD feeding was also reported for rats harboring the same microbial community ([@B18]). This finding is consistent with increased proportions of *Erysipelotrichi* in obese mice and in a human patient ([@B5][@B6][@B8]). However, the reason for the observed increase in *C. ramosum* in HFD-fed obese SIHUMI mice or SIHUMI rats is unknown. Bile acids produced in response to HFD possibly promoted the growth of *C. ramosum*, because administration of cholic acid was demonstrated to increase the proportion of intestinal *Firmicutes*, in particular that of *Erysipelotrichi* ([@B28]). More recent human studies reported a link between the abundance of *C. ramosum* and parameters of the metabolic syndrome ([@B9], [@B10]). We therefore hypothesized that *C. ramosum* contributes to obesity development.

*C. ramosum* promotes accumulation of body fat. {#h2.2}
-----------------------------------------------

To investigate the hypothesized obesogenic effect of *C. ramosum* alone or as a member of a defined microbial community, we compared Cra, SIHUMI, and SIHUMIw/oCra mice, all fed HFD. Cra and SIHUMI mice displayed more pronounced symptoms of obesity, such as increased accumulation of body fat compared with SIHUMIw/oCra mice ([Fig. 2](#fig2){ref-type="fig"}). Hence, the obesogenic effect of *C. ramosum* was observed in two different mouse models: mice monoassociated with *C. ramosum* and mice harboring the SIHUMI community. However, it is not clear whether this effect is restricted to the particular HFD used in our experiments or whether it would also be observed in response to feeding on other energy-rich diets. Moreover, it would be important to find out whether species other than *C. ramosum* may have obesogenic effects, in particular members of the *Erysipelotrichi*, including *Eubacterium dolichum* and *Clostridium innocuum*, which were increased in the Western diet-associated microbiome ([@B6], [@B7]). Recently, an obesity-promoting effect was demonstrated for the proteobacterium *Enterobacter cloacae* in monoassociated mice ([@B29]). However, the contribution of this endotoxin-producing species to obesity development as a member of a defined microbial community was not investigated in the study by Fei and Zhao ([@B29]).

In line with the reported correlation between the fecal abundance of *Erysipelotrichi* and the hepatic fat content in humans ([@B30]), we found high hepatic triglyceride levels in mice harboring *C. ramosum* ([Fig. 3](#fig3){ref-type="fig"}). Unexpectedly, SIHUMI and Cra mice differed in hepatic lipogenesis and oxidation markers, indicating that mechanisms involved in fat storage in adipose tissue differed between these mice. Obesity of SIHUMI and Cra mice was associated with neither a higher energy intake nor impaired gut barrier function or metabolic endotoxemia. Other explanations for differences in the susceptibility to HFD-induced obesity include reduced energy expenditure ([@B5]) or reduced thermogenesis as brought about by saturated fatty acids in HFD ([@B31]). However, these factors do not explain the differences between the obese SIHUMI or Cra mice and the less obese SIHUMIw/oCra mice, since all mice were fed the same HFD. Therefore, *C. ramosum* must be responsible for the obesity-promoting effects observed in SIHUMI and Cra mice.

SCFA formation does not explain the obesogenic effect of *C. ramosum*. {#h2.3}
----------------------------------------------------------------------

SCFA produced by intestinal bacteria deliver additional energy to the host and could therefore contribute to obesity development ([@B7], [@B12], [@B23]). However, digestibility of the HFD did not differ between obese and less obese mice. Moreover, three observations argue against the idea that SCFA promoted obesity in SIHUMI and Cra mice: (i) Cra mice became obese despite very low intestinal SCFA concentrations, (ii) SIHUMI and Cra mice stayed lean on LFD even though intestinal SCFA concentrations were as high as those of the respective HFD-fed mice (data not shown), and (iii) SCFA concentrations in portal vein plasma were not increased in obese SIHUMI mice.

Upregulation of *Glut2* transcription in small intestine may be involved in the obesogenic effect of *C. ramosum*. {#h2.4}
------------------------------------------------------------------------------------------------------------------

Gut bacteria have also been proposed to promote obesity by a more efficient absorption of monosaccharides in the intestine ([@B13]). Regulation of mucosal gene expression by intestinal bacteria might be critically involved in this effect ([@B20], [@B32]). SIHUMI and Cra mice displayed an improved food efficiency ([Table 1](#tab1){ref-type="table"}), suggesting that *C. ramosum* alone or as a SIHUMI member promoted the uptake of obesogenic nutrients. The increased small intestinal expression of *Glut2* observed in SIHUMI and Cra mice argues in favor of increased glucose absorption as a factor that contributed to the obesogenic effect of *C. ramosum*. The high glucose uptake may have impaired glucose homeostasis in Cra mice. However, such an effect was not observed in SIHUMI mice, suggesting that the microbial community in SIHUMI mice prevented the prediabetic signs observed in the Cra mice.

Increased transcription of fat transporters in ileum may contribute to the obesogenic effect of *C. ramosum*. {#h2.5}
-------------------------------------------------------------------------------------------------------------

We hypothesized that elevated lipid absorption could be a mechanism by which *C. ramosum* promotes obesity. A study comparing conventional and germfree mice revealed that the intestinal microbiota increases intestinal absorption of lipids, resulting in better food efficiency and marked obesity ([@B33]). Recently, it has also been demonstrated that gut bacteria induce the absorption of long-chain and medium-chain fatty acids as well as the formation of lipid droplets in intestinal epithelium of zebrafish ([@B17]), whereas they do not affect the absorption of triglycerides ([@B34]). Proteins such as CD36, FATP4, and FABP2 are involved in intestinal lipid uptake and signaling ([@B35], [@B36]). The protein PLIN2 coats lipid droplets and is involved in intracellular fat storage in enterocytes ([@B37], [@B38]). The increased expression of *Cd36* in ileum of Cra and SIHUMI mice suggests that the presence of *C. ramosum* promoted the transcription of this gene and thereby contributed to obesity development. SIHUMI mice but not SIHUMIw/oCra or Cra mice displayed elevated mRNA levels of *Fatp4* and *Plin2* in ileum. This indicates that the *C. ramosum*-mediated increase in transcription of these genes in the SIHUMI mice was dependent on the interaction with other community members.

In summary, this study reveals that the presence of *C. ramosum* in SIHUMI and Cra mice is accompanied by increased body weight gain and body fat storage compared with SIHUMIw/oCra mice after being fed an HFD for 4 weeks, suggesting that *C. ramosum* has obesogenic properties under these experimental conditions. Upregulation of *Glut2* and *Cd36* transcription in small intestinal mucosa in gnotobiotic mice harboring intestinal *C. ramosum* indicates that this organism promotes body fat accumulation through enhanced intestinal glucose and lipid absorption. Mechanistic research is needed to prove this hypothesis---for instance, by taking advantage of labeled substrates. Which bacterial molecules mediate these obesogenic effects is still unclear and deserves further investigations. We cannot exclude that *C. ramosum* promoted obesity through additional mechanisms not investigated in this study, including modifications in energy expenditure or in adipose tissue and muscle lipid metabolism. To find out whether the observed ability of *C. ramosum* to promote obesity is a general feature of this species or restricted to the strain under study, additional *C. ramosum* strains and other members of the *Erysipelotrichi* apart from *C. ramosum* need to be investigated in more complex microbial communities. Unraveling the underlying mechanism may help to develop new strategies in the prevention or treatment of obesity.

MATERIALS AND METHODS {#h3}
=====================

Mice and experimental setup. {#h3.1}
----------------------------

Germfree male C3H/HeOuJ mice were obtained from the gnotobiotic animal facility of the German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany. The mice were maintained in positive-pressure isolators (Metall & Plastik, Radolfzell, Germany) under a 12-h light-dark cycle. They were kept individually in polycarbonate cages on irradiated wood chips (25 to 50 kGy) at 22 ± 2°C and 55% ± 5% air humidity. All mice had free access to irradiated standard chow (Altromin fortified type 1310; Altromin, Lage, Germany) and autoclaved water. The animal experiments were approved by the Animal Welfare Committee of the State of Brandenburg (approval no. V3-2347-10-2011). Germfree mice were associated with a simplified bacterial community of human intestinal bacteria (SIHUMI) consisting of *Anaerostipes caccae* DSM 14662, *Bacteroides thetaiotaomicron* DSM 2079, *Bifidobacterium longum* NCC 2705, *Blautia producta* DSM 2950, *Clostridium butyricum* DSM 10702, *Clostridium ramosum* DSM 1402, *Escherichia coli* K-12 MG1655, and *Lactobacillus plantarum* DSM 20174 ([@B18]). A second group of germfree mice was associated with all SIHUMI members except *C. ramosum* (SIHUMIw/oCra). Association of germfree mice with bacteria and confirmation of successful colonization were performed as described previously for rats ([@B18]). Male offspring of these mice were used for the experiments. A third group of germfree male mice was monoassociated with *C. ramosum* (Cra) at the age of 6 weeks. Twelve-week-old SIHUMI, SIHUMIw/oCra, and Cra mice (*n* = 8 to 9) were either fed *ad libitum* a semisynthetic LFD or an HFD ([Table 4](#tab4){ref-type="table"}) for 4 weeks. Body weight and feed intake were determined weekly. Energy intake and fecal energy loss within 48 h were determined by bomb calorimetry during the third intervention week and used for the calculation of diet digestibility and digestible energy as described before ([@B5]). Glucose tolerance was determined using an oral glucose tolerance test 2 days prior to killing. After an overnight fast (16 h), glucose (2 g/kg body weight) was administered orally, and tail vein blood was taken at gavage and 15, 30, 60, and 120 min after gavage. Glucose concentrations were analyzed using Contour glucose sticks (Bayer, Leverkusen, Germany). The total area under the curve (AUC) of blood glucose concentration was calculated.

###### 

Composition of the semisynthetic LFD and the HFD and energy measurements

  Parameter                         Result for:   
  --------------------------------- ------------- ------
  Ingredients (g/100 g)                           
      Casein                        27            22
      Wheat starch                  15            38
      Maltodextrin                  14            14
      Sucrose                       10            10
      Palm kernel fat (Palmin)      11            2
      Sunflower oil                 11            2
      Cellulose                     5             5
      Mineral mixture               5             5
      Vitamin mixture               2             2
  Energy (kJ/g)^[*a*](#ngtab4.1)^   20.6          17.3
  Energy (%) from:                                
      Protein                       22.7          23.8
      Carbohydrate                  32.6          65.7
      Fat                           44.7          10.5

Determined by bomb calorimetry.

Intestinal permeability *in vivo.* {#h3.2}
----------------------------------

Intestinal permeability was measured using the FITC-dextran assay in the fourth intervention week as previously described ([@B14]), with some modifications. Mice were fasted for 6 h and subsequently given 4-kDa FITC-dextran (Sigma-Aldrich, Munich, Germany) by gavage (600 mg/kg body weight \[80 mg/ml\]). The FITC-dextran solution was prepared with phosphate-buffered saline (PBS: NaCl, 8.0 g/liter; KCl, 0.2 g/liter; Na~2~HPO~4~, 1.44 g/liter; KH~2~PO~4~, 0.24 g/liter \[pH 7.4\]) and sterile filtered. One hour after gavage, 90 µl blood was collected from the retrobulbar capillary plexus in heparinized tubes. After centrifugation at 2,000 × *g* for 5 min, the plasma was diluted 1/5 with PBS. FITC-dextran concentrations were measured spectrophotometrically (Infinite M200 PRO; Tecan, Grödig, Austria) at an excitation wavelength of 485 nm and an emission wavelength of 528 nm. Standards were prepared in PBS, and the generated curve was used to calculate the FITC-dextran concentrations in the collected samples.

Body composition and tissue sampling. {#h3.3}
-------------------------------------

After 4 weeks of dietary intervention, body composition was determined by quantitative magnetic resonance spectroscopy (MQ10; Bruker Minispec, Houston, TX) as previously described ([@B39]). Subsequently, the nonfasted mice were anesthetized, and blood was taken from the retrobulbar plexus, followed by cervical dislocation of the mice. Liver, eWAT, mesenteric white adipose tissue (mWAT), and subcutaneous white adipose tissue (sWAT) were weighed. Mucosa was scraped from jejunum, ileum, and colon. All tissues were frozen in liquid nitrogen and stored at −80°C. Gut contents were collected and stored at −20°C for further analyses.

Gut content analyses. {#h3.4}
---------------------

The microbial composition of cecal and colonic contents was analyzed by fluorescence *in situ* hybridization and plating on Rogosa agar (Oxoid Limited, Hampshire, United Kingdom) ([@B18]). SCFA in gut contents were analyzed by gas chromatography as previously described ([@B5]), but the sample weight was reduced to approximately 40 mg, and the volume of all solvents was halved. SCFA formation capacity of intestinal contents and SCFA concentrations in portal vein plasma were determined by analyzing three additional SIHUMI and SIHUMIw/oCra mice, respectively (see [Text S1](#supplS1){ref-type="supplementary-material"} in the supplemental material).

Plasma analyses. {#h3.5}
----------------

LPS analysis with the *Limulus* amebocyte lysate (LAL) kinetic chromogenic methodology was performed by Charles River Laboratories (L'Arbresle Cedex, France). Color absorbance was directly proportional to the endotoxin concentration. Prior to the test, peripheral blood plasma was diluted 1/50 with LAL reagent water and heated for 10 min at 70°C.

Liver triacylglycerol and glycogen analyses. {#h3.6}
--------------------------------------------

An aliquot of ground liver tissue (50 mg) was used for liver triglyceride and glycogen analysis, respectively. Triglycerides and glycogen were extracted as described previously ([@B5]). Triglycerides were enzymatically hydrolyzed by the lipolytic activity of the triglyceride reagent (Sigma-Aldrich) to glycerol and free fatty acids. Free glycerol was measured by coupled enzyme reactions with the free glycerol reagent (Sigma-Aldrich). Liver glycogen was determined with the Starch kit (R-Biopharm, Darmstadt, Germany). Glycogen was hydrolyzed, and the glucose formed was further oxidized, leading to the formation of reduced NADPH. Glycogen and triglyceride contents were related to the protein content of the samples as measured with the detergent-compatible protein assay (Bio-Rad, Hercules, CA), a modified colorimetric Lowry assay. All measurements were performed in triplicates in 96-well plates.

Quantitative real-time PCR. {#h3.7}
---------------------------

RNA from intestinal mucosa, liver, and fat tissue was isolated with the peqGOLD TriFast reagent (Peqlab, Erlangen, Germany). Genomic DNA was removed using the Ambion Turbo DNA-free kit (Life Technologies, Darmstadt, Germany). Removal of genomic DNA was considered successful when no amplification of 18S rRNA genes (*Rn18s*) was detectable. Integrity of RNA was verified by running aliquots on agarose gels stained with ethidium bromide. Complementary DNA was synthesized from 1 µg of total RNA with the RevertAid H Minus first-strand cDNA synthesis kit (Thermo Scientific, Schwerte, Germany). Quantitative PCR was performed with the Applied Biosystems 7900 HT fast real-time PCR system (Life Technologies). The reaction mixture of 5 µl contained 2.5 µl Power SYBR green PCR master mix or TaqMan gene expression master mix (Life Technologies), primers (3 µM each) (for sequences, see [Table S3](#tabS3){ref-type="supplementary-material"} in the supplemental material), and a cDNA amount corresponding to 5 ng of RNA. An oligonucleotide probe (2 µM) ([Table S3](#tabS3){ref-type="supplementary-material"}) was added to the TaqMan reaction mixture. Gene expression was calculated using the threshold cycle (ΔΔ*C*~*T*~) method ([@B40]).

Statistical analysis. {#h3.8}
---------------------

Data are presented as means ± standard errors of the means (SEM). The Gaussian distribution of all data was checked with the Kolmogorov-Smirnov test. Normally distributed data sets were tested for statistical significance of difference using Student's *t* test, whereas nonnormally distributed data were analyzed with the Mann-Whitney *U* test using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA). LPS and FITC-dextran outliers were identified with the Grubbs test using a free web calculator (http://graphpad.com/quickcalcs) and removed from the data set.

SUPPLEMENTAL MATERIAL {#h4}
=====================

###### 

Supplemental methods. Download

###### 

Text S1, DOC file, 0.02 MB

###### 

Relative body weight gain during 4 weeks of dietary intervention (A, B, and C) and body fat percentage after 4 weeks of dietary intervention (D) of mice harboring a simplified human intestinal microbiota (SIHUMI), SIHUMI without *C. ramosum* (SIHUMIw/oCra), or *C. ramosum* only (Cra). All mice were fed a high-fat diet (HFD) or a low-fat diet (LFD). Values are means ± SEM. *n* = 8 to 9 mice per group, except for the body fat percentage of Cra mice, for which *n* = 3. \*, *P* \< 0.05, \*\*, *P* \< 0.01, and \*\*\*, *P* \< 0.001, for HFD-fed mice versus LFD-fed mice. Download

###### 

Figure S1, PDF file, 0.1 MB

###### 

Bacterial cell counts in the intestine of mice harboring a simplified human intestinal microbiota (SIHUMI) fed low-fat diet (LFD) or high-fat diet (HFD) for 4 weeks.

###### 

Table S1, DOC file, 0.04 MB.

###### 

*In vitro* short-chain fatty acid (SCFA) formation capacity of SIHUMI and SIHUMIw/oCra communities and portal plasma SCFA concentrations in SIHUMI and SIHUMIw/oCra mice.
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Table S2, DOC file, 0.03 MB.

###### 

Sequences of primers and probes used for quantitative real-time PCR.

###### 

Table S3, DOC file, 0.1 MB.
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